TORONTO, CANADA — (Dec 1, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Thursday, November 26 for the fiscal quarter ended September 30, 2015. The Corporation’s unaudited Q2 2016 financial statements and MD&A are available on SEDAR.
Antibe’s financial statements and operating results to September 30, 2015 do not include results from Citagenix, which was purchased on October 15, 2015 (see earlier press release for details of this transaction). The Citagenix purchase represents Antibe’s initial entry into the regenerative medicine business. Financial and operating results for Citagenix will be reflected in Antibe’s results for the quarter ended December 31, 2015.
Antibe is also pleased to announce the appointment of Alain Wilson to the position of Chief Financial Officer. Alain is a management consultant with extensive experience in strategy and financial analysis in a variety of industries, including healthcare. Over the last 30 years Alain has worked with senior executives on key strategic issues both in North America and internationally. He was a Vice President and Toronto Office Head for Mercer Management Consulting (now Oliver Wyman), and more recently a founding partner of Revelstoke Partners, a boutique consulting firm focused on assisting mid-market companies. Alain has also served as CFO, or acting CFO, of several private and public companies. Alain has an Honours Bachelor of Commerce degree from Queen’s University and a Masters of Business Administration from IMD in Switzerland.
About Antibe Therapeutics Inc.Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com
Antibe's subsidiary, Citagenix Inc. ("Citagenix"), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking InformationThis news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.
Contact InformationAntibe Therapeutics Inc.
Chief Executive Officer
Tel: +1 416-473-4095